Listing of the Claims

1-5. Cancelled.

6. (New) A method of elevating white blood cell count in a mammal comprising:

a) providing a CLA composition comprising t10,c12 octadecadienoic acid and c9,t11 octadecadienoic acid in a ratio of about 1.2:1 to 3:1 and a mammal; and

b) administering said CLA composition to said mammal under conditions such that the white blood cell count of the mammal is elevated.

7. (New) The method of Claim 6, wherein said white blood cells are selected from the group consisting of B cells, T cells and Natural Killer cells.

8. (New) The method of Claim 6, wherein said CLA composition is administered orally.

9. (New) The method of Claim 6, wherein said CLA composition comprises free fatty acids of t10,c12 octadecadienoic acid and c9,t11 octadecadienoic acid

10. (New) The method of Claim 6, wherein said CLA composition comprises esters of t10,c12 octadecadienoic acid and c9,t11 octadecadienoic acid.

11. (New) The method of Claim 6, wherein said CLA composition comprises acylglycerides of t10,c12 octadecadienoic acid and c9,t11 octadecadienoic acid.

12. (New) A method of treating type I or IgE mediated hypersensitivity in a mammal comprising:

a) providing a CLA composition comprising t10,c12 octadecadienoic acid and c9,t11 octadecadienoic acid in a ratio of about 1.2:1 to 3:1 and a mammal; and

b) administering said CLA composition to said mammal under conditions such that said type I or IgE mediated hypersensitivity is reduced.

13. (New) The method of Claim 7, wherein said white blood cells are selected from the group consisting of B cells, T cells and Natural Killer cells.

14. (New) The method of Claim 7, wherein said CLA composition is administered orally.

15. (New) The method of Claim 7, wherein said CLA composition comprises free fatty acids of t10,c12 octadecadienoic acid and c9,t11 octadecadienoic acid

16. (New) The method of Claim 7 wherein said CLA composition comprises esters of t10,c12 octadecadienoic acid and c9,t11 octadecadienoic acid.

17. (New) The method of Claim 7, wherein said CLA composition comprises acylglycerides of t10,c12 octadecadienoic acid and c9,t11 octadecadienoic acid.